SuperworthScienture SCNX
- Market cap
- $4.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Scienture's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $392.3K−81% | $128.7K−94% | n/a | $18.7K−95% | $64.9K−84% | $53.1K−59% | $10.3K | $0 | $590K+810% | n/a | $56.3K+449% | $343.6K | |
| Cost of revenue | $352.7K−48% | $242.6K−67% | n/a | $19.4K−94% | $61K−83% | $50.3K−79% | $9.6K | $0 | $15.4K−75% | n/a | $2.5K−74% | $7.9K |
| Gross profit | $39.6K−97% | −$114K | n/a | −$703 | $3.9K−90% | $2.8K | $673 | $0 | $574.6K+14698% | n/a | $53.9K+7902% | $335.8K |
| R&D | n/a | n/a | n/a | n/a | $1.3M | $982.7K | $574.7K | $843.5K | $169.3K−87% | n/a | $794K+38% | $1.2M+38% |
| SG&A | $66.9K−71% | $853.3K+187% | $4.7M+1795% | $415.4K+145% | $168.6K+152% | $1.4M+63% | $1.4M−71% | $2.9M+605% | $2.2M+1184% | n/a | $1.1M−21% | $368.8K−87% |
| −$761.7K+248% | −$2.3M+112% | −$5.5M+581% | −$1.5M+149% | −$3.5M+359% | −$4.2M+87% | −$3.6M−35% | −$5.2M+245% | −$4.4M+25% | n/a | −$3.5M−2% | −$2.7M−48% | |
| Interest expense | $251.8K+94% | $648.3K+232% | $98.5K+58% | $4.9K−97% | $217.4K−14% | $1M+57% | $670.8K+581% | $653.5K+13105% | $1.8M+729% | n/a | $37K−95% | $269.8K−59% |
| Pre-tax income | n/a | n/a | −$6.6M | −$1.6M | −$3.2M | −$7.3M | −$3.1M−54% | −$6.7M+314% | −$3.6M+13% | n/a | n/a | n/a |
| Net income | −$3.5M+601% | −$11.7M+1161% | $21.2M | −$1.8M−7% | −$3.2M−10% | −$7.2M−39% | −$3.1M | −$6.7M+267% | −$3.6M+13% | −$28.1M+293% | −$3.4M+11% | −$2.8M−58% |
| −$114.25+402% | −$313.50+736% | $419.25 | −$32.50−55% | −$33.50−71% | −$20.75−93% | −$8.25 | −$12.00−63% | −$4.75−86% | −$38.00+83% | −$2.00−76% | −$1.75−85% | |
| 94.5K+328% | 37.2K+50% | 50.7K+89% | 56.3K+107% | 95K+0% | 345.2K+828% | 377K+644% | 565.7K+906% | 758.3K+699% | 741.8K+115% | 1.6M+331% | 1.6M+180% |
Revenue: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
SG&A: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Net income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
EPS, diluted: 14 periods, Q4 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Scienture's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SCNXScienture | $4.7M | n/m | n/a | n/m | n/m | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on Scienture
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .